Vanderbilt-Ingram Cancer Center

Nancy Davis, MD, has been promoted to Vice President for Cancer Care Network and Strategy at Vanderbilt University Medical Center, a new position responsible for developing provider relationships with other health care systems and expanding access to oncology care throughout Tennessee and other states.

A team of Vanderbilt researchers have shown in a preclinical study that the investigational drug rigosertib could be a potential booster treatment to elicit response to immunotherapies among melanoma patients.

Christine Lovly, MD, PhD, is the recipient of the 2021 ECOG-ACRIN Young Investigator Award, a major recognition of research excellence.

A significant reduction in annual well visits and immunizations during the COVID-19 pandemic has led to a vaccination gap among U.S. children and adolescents, especially with the human papillomavirus (HPV) vaccine for cancer prevention.

Vanderbilt-Ingram Cancer Center researchers will present data on clinical trials involving targeted therapies, immunotherapies and drug combination synergies at the 2021 American Society of Clinical Oncology Annual Meeting, June 4-8. The meeting is a virtual event this year.

Their condominium in The Westbury was at the heart of all that William and Frances Blot loved about Nashville — its proximity to Vanderbilt where he worked for two decades, its sidewalk that led to the greenspaces where they would watch the seasons change, and its residents who became more like friends than neighbors.

People with a high polygenic risk score for colorectal cancer could benefit more at preventing the disease by leading healthy lifestyles than those at lower genetic risk, according to a study by Vanderbilt researchers published in the April issue of The American Journal of Clinical Nutrition.